RNA Repair in Neuromuscular Disease: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

RNA repair is emerging as a critical biological process with significant implications for the pathogenesis and treatment of neuromuscular diseases. Recent advances in molecular medicine have revealed that defects in RNA processing and repair contribute to a range of neuromuscular disorders, including spinal muscular atrophy, myotonic dystrophy, and amyotrophic lateral sclerosis. This review synthesizes current scientific evidence on the role of RNA repair mechanisms, details their relevance to disease burden, elucidates pathophysiological pathways, and evaluates clinical implications and therapeutic strategies. Attention is given to both established and novel RNA-targeted interventions, providing clinicians and researchers with a comprehensive overview of the field and its translational potential.

Introduction

Neuromuscular diseases (NMDs) encompass a heterogeneous group of disorders characterized by progressive weakness and degeneration of skeletal muscles and motor neurons. While genetic mutations have long been recognized as causative, recent research highlights the pivotal role of post-transcriptional RNA processes, especially RNA repair, in both disease onset and progression. RNA repair refers to the cellular capacity to recognize, excise, and restore damaged or misprocessed RNA, thus maintaining transcriptome integrity. Disruption of these mechanisms can result in aberrant protein expression, toxic RNA species, and ultimately neuromuscular dysfunction. This review aims to provide a comprehensive and clinically relevant synthesis of RNA repair mechanisms in NMDs, integrating evidence from molecular biology, clinical research, and emerging therapeutic approaches.

Epidemiology / Disease Burden

Neuromuscular diseases affect millions globally, with a substantial impact on morbidity, mortality, and healthcare resources. Disorders such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) each have an incidence of approximately 1-2 per 100,000 individuals, whereas myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy. The burden is amplified by chronic disability, frequent hospitalizations, and a lack of curative therapies. Population studies indicate that defects in RNA metabolism are implicated in a significant proportion of both inherited and sporadic NMDs, underscoring the importance of understanding RNA repair as a therapeutic target.

Pathophysiology

The pathophysiology of RNA repair in NMDs involves complex interactions between genetic mutations, RNA-binding proteins, and cellular stress responses. In SMA, for example, mutations in the SMN1 gene compromise the assembly of small nuclear ribonucleoproteins (snRNPs), resulting in defective splicing and destabilization of motor neuron-specific RNAs. In ALS, mutations in genes encoding RNA-binding proteins such as TDP-43 and FUS disrupt normal RNA metabolism, leading to RNA mislocalization, aggregation, and toxicity. Myotonic dystrophy is characterized by expanded nucleotide repeats in non-coding regions that sequester RNA-binding proteins, impairing splicing and repair mechanisms. Defective RNA repair pathways contribute to the accumulation of damaged transcripts, impaired protein synthesis, and cellular degeneration.

Risk Factors

Genetic predisposition is the primary risk factor for RNA repair-related neuromuscular diseases, including inherited point mutations, nucleotide repeat expansions, and chromosomal rearrangements affecting RNA processing genes. Environmental factors such as oxidative stress, viral infections, and toxic exposures may exacerbate RNA damage or overwhelm repair capacity, accelerating disease progression. Age is a significant risk modifier, with age-related decline in RNA surveillance mechanisms possibly facilitating the onset of late-onset neuromuscular disorders. Epigenetic factors, including alterations in RNA methylation and non-coding RNA expression, are increasingly recognized as modulators of RNA repair efficiency and disease susceptibility.

Clinical Features

The clinical spectrum of neuromuscular diseases linked to RNA repair defects is broad, reflecting the diversity of affected RNA targets and tissue specificity. Common features include progressive muscle weakness, atrophy, and fasciculations, often accompanied by bulbar and respiratory involvement in severe cases. In SMA, proximal muscle weakness and hypotonia dominate the clinical picture, while ALS is characterized by a combination of upper and lower motor neuron signs. Myotonic dystrophy presents with muscle stiffness, myotonia, cataracts, and multisystem involvement. Cognitive impairment, cardiac conduction defects, and endocrine abnormalities may be observed in select disorders, emphasizing the systemic impact of disrupted RNA repair.

Diagnosis

Diagnosis of RNA repair-associated NMDs relies on a combination of clinical evaluation, electrophysiological studies, muscle biopsy, and advanced genetic and molecular testing. Next-generation sequencing enables the identification of causative mutations in RNA-binding proteins and repair enzymes. RNA sequencing (RNA-seq) and transcriptome analysis can reveal aberrant splicing events, cryptic exon inclusion, and accumulation of damaged RNA species. Biomarkers such as misprocessed RNA or dysregulated microRNAs are being investigated for early diagnosis and disease monitoring. Electromyography and nerve conduction studies assist in characterizing the pattern and severity of neuromuscular involvement.

Treatment & Management

Current management strategies for neuromuscular diseases associated with RNA repair defects are primarily supportive, focusing on symptom control, physical therapy, pulmonary care, and nutritional support. Pharmacological interventions target downstream effects, including antispastic agents, anticonvulsants, and cardiac medications. Disease-modifying therapies have been developed for specific conditions, such as nusinersen and risdiplam for SMA, which modulate splicing of SMN2 to enhance functional protein production. Multidisciplinary care is essential to address the complex needs of affected individuals and improve quality of life.

Recent Advances / Emerging Therapies

Therapeutic strategies targeting RNA repair and processing have shown promise in preclinical and clinical studies. Antisense oligonucleotides (ASOs) are at the forefront, correcting splicing defects or promoting degradation of toxic RNA species. Small molecule modulators of RNA-binding proteins and RNA-editing enzymes are under active investigation. RNA-guided endonucleases, such as CRISPR-Cas13, offer the potential for precise correction of pathogenic RNA sequences. Gene therapy approaches, including adeno-associated virus-mediated delivery of functional RNA repair genes, are being explored for diseases with monogenic origins. These advances underscore the translational potential of RNA repair research and its promise for future clinical application.

Guideline Recommendations

Consensus guidelines from international neurology and genetics societies emphasize early diagnosis, multidisciplinary management, and the integration of genetic testing in suspected cases of RNA repair-related NMDs. Disease-specific recommendations highlight the use of splicing modulators in SMA and the need for regular cardiac and respiratory monitoring in myotonic dystrophy. Genetic counseling is advised for affected families. Regulatory agencies recommend ongoing participation in clinical trials evaluating RNA-targeted therapies, given the rapid evolution of the field and the need for real-world efficacy and safety data.

Conclusion

RNA repair has emerged as a central mechanism in the pathogenesis and potential treatment of neuromuscular diseases. Advances in molecular diagnostics and therapeutics are transforming the clinical landscape, offering hope for targeted, disease-modifying interventions. Continued research into RNA repair pathways will be essential for developing personalized medicine approaches and improving outcomes for patients with these challenging disorders.